KRYS
Krystal Biotech, Inc.
Price Chart
Latest Quote
$347.63
+7.42 (+2.18%)
Current Price
| Previous Close | $340.21 |
| Open | $343.59 |
| Day High | $353.89 |
| Day Low | $343.59 |
| Volume | 354,253 |
Stock Information
| Shares Outstanding | 29.48M |
| Total Debt | $9.11M |
| Cash Equivalents | $823.40M |
| Revenue | $417.30M |
| Net Income | $225.03M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $10.61B |
| P/E Ratio | 48.12 |
| EPS (TTM) | $7.48 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $9.43B |
| Sales | $417.30M |
| Income | $225.03M |
| Book/sh | $43.37 |
| Cash/sh | $27.93 |
| Employees | 295 |
Financial Ratios
| Quick Ratio | 8.82 |
| Current Ratio | 9.46 |
| Debt/Eq | 0.71 |
| EPS Growth TTM | 56.50% |
Returns & Margins
| ROA | 9.04% |
| ROE | 19.90% |
| Gross Margin | 94.17% |
| Operating Margin | 46.14% |
| Profit Margin | 53.92% |
Ownership
| Insider Ownership | 10.97% |
| Institutional Ownership | 99.36% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 35.72 |
| P/S | 25.43 |
| P/B | 8.30 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $349.78 |
Technical Indicators
| SMA20 | $320.69 |
| SMA50 | $300.76 |
| SMA200 | $248.17 |
| RSI | 78.54 |
| ATR | 12.9803 |
| Shares Float | 23.42M |
| Short Float | 17.53% |
| Short Ratio | 10.55 |
| Volatility | 0.53 |
| Rel Volume | 0.99 |
Performance History
| Week | +5.35% |
| Month | +18.91% |
| Quarter | +41.18% |
| 6 Months | +44.20% |
| YTD | +45.77% |
| Year | +150.53% |
| 3 Years | +188.47% |
| 5 Years | +466.91% |
| 10 Years | +3282.80% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $359.93 | 329,642 |
| 2026-06-24 | $347.63 | 378,300 |
| 2026-06-23 | $340.21 | 272,700 |
| 2026-06-22 | $343.43 | 411,600 |
| 2026-06-18 | $348.06 | 811,400 |
| 2026-06-17 | $341.66 | 514,600 |
| 2026-06-16 | $323.37 | 328,900 |
| 2026-06-15 | $324.75 | 263,500 |
| 2026-06-12 | $317.97 | 302,300 |
| 2026-06-11 | $321.55 | 477,400 |
| 2026-06-10 | $312.41 | 301,900 |
| 2026-06-09 | $309.75 | 233,100 |
| 2026-06-08 | $301.76 | 259,700 |
| 2026-06-05 | $301.00 | 264,400 |
| 2026-06-04 | $307.79 | 264,900 |
| 2026-06-03 | $301.82 | 240,400 |
| 2026-06-02 | $293.21 | 334,000 |
| 2026-06-01 | $298.10 | 262,900 |
| 2026-05-29 | $309.03 | 226,300 |
| 2026-05-28 | $310.30 | 174,000 |
| 2026-05-27 | $306.63 | 144,300 |
| 2026-05-26 | $302.68 | 181,900 |
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
đ° Latest News
The Brown Capital Management Small Company Fund Bets on Krystal Biotech (KRYS) for Its Resilient Revenue Stream
Insider Monkey âĸ 2026-06-24T13:55:13Z
3 Biotech Firms With Major Potential Catalysts in the Coming Months
MarketBeat âĸ 2026-06-21T14:30:00Z
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead
Motley Fool âĸ 2026-06-18T05:50:00Z
These Are 5 Of The Best Stocks To Buy Or Watch Now
Investor's Business Daily âĸ 2026-06-15T13:26:02Z
Exploring 3 High Growth Tech Stocks in US Market
Simply Wall St. âĸ 2026-06-15T11:39:04Z
Viking, Bloom Energy Lead Five Stocks Making Bullish Moves As Market Rebounds
Investor's Business Daily âĸ 2026-06-13T12:00:50Z
Dow Jones Futures Rise, Oil Skids On Iran Deal Hopes; SpaceX IPO Indicated Higher
Investor's Business Daily âĸ 2026-06-12T12:11:14Z
Exploring High Growth Tech Stocks In The US Market
Simply Wall St. âĸ 2026-06-11T11:38:33Z
Exploring 3 High Growth Tech Stocks in the US Market
Simply Wall St. âĸ 2026-06-09T11:38:22Z
Is Krystal Biotech, Inc. (KRYS) A Good Stock To Buy Now?
Insider Monkey âĸ 2026-06-07T17:18:15Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $23,049,000 | $20,061,000 | $3,094,000 | $0 |
| Cost Of Revenue | $23,049,000 | $20,061,000 | $3,094,000 | $0 |
| Total Revenue | $389,130,000 | $290,515,000 | $50,699,000 | $0 |
| Operating Revenue | $389,130,000 | $290,515,000 | $50,699,000 | $0 |
| Expenses | ||||
| Total Expenses | $227,835,000 | $187,267,000 | $147,816,000 | $120,196,000 |
| Net Non Operating Interest Income Expense | $28,176,000 | $29,608,000 | $22,514,000 | $5,221,000 |
| Operating Expense | $204,786,000 | $167,206,000 | $144,722,000 | $120,196,000 |
| Other Income Expense | - | $-37,500,000 | $87,500,000 | $-25,000,000 |
| Interest Expense | - | - | $0 | $0 |
| Interest Expense Non Operating | - | - | $0 | $0 |
| General And Administrative Expense | - | - | - | $77,735,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $204,831,000 | $89,159,000 | $10,932,000 | $-139,975,000 |
| Net Interest Income | $28,176,000 | $29,608,000 | $22,514,000 | $5,221,000 |
| Interest Income | $28,176,000 | $29,608,000 | $22,514,000 | $5,221,000 |
| Normalized Income | $204,831,000 | $124,221,948 | $-63,236,411 | $-114,975,000 |
| Net Income From Continuing And Discontinued Operation | $204,831,000 | $89,159,000 | $10,932,000 | $-139,975,000 |
| Total Operating Income As Reported | $161,295,000 | $65,748,000 | $-109,617,000 | $-145,196,000 |
| Net Income Common Stockholders | $204,831,000 | $89,159,000 | $10,932,000 | $-139,975,000 |
| Net Income | $204,831,000 | $89,159,000 | $10,932,000 | $-139,975,000 |
| Net Income Including Noncontrolling Interests | $204,831,000 | $89,159,000 | $10,932,000 | $-139,975,000 |
| Net Income Continuous Operations | $204,831,000 | $89,159,000 | $10,932,000 | $-139,975,000 |
| Pretax Income | $189,471,000 | $95,356,000 | $12,897,000 | $-139,975,000 |
| Special Income Charges | $0 | $-37,500,000 | $87,500,000 | $-25,000,000 |
| Interest Income Non Operating | $28,176,000 | $29,608,000 | $22,514,000 | $5,221,000 |
| Operating Income | $161,295,000 | $103,248,000 | $-97,117,000 | $-120,196,000 |
| Gross Profit | $366,081,000 | $270,454,000 | $47,605,000 | $0 |
| Per Share | ||||
| Diluted EPS | $6.84 | $3.00 | $0.39 | $-5.49 |
| Basic EPS | $7.08 | $3.12 | $0.40 | $-5.49 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-2,437,052 | $13,331,589 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $167,846,000 | $147,462,000 | $-178,706,000 | $-91,811,000 |
| Total Unusual Items | $0 | $-37,500,000 | $87,500,000 | $-25,000,000 |
| Total Unusual Items Excluding Goodwill | $0 | $-37,500,000 | $87,500,000 | $-25,000,000 |
| Reconciled Depreciation | $6,551,000 | $6,714,000 | $5,911,000 | $3,385,000 |
| EBITDA (Bullshit earnings) | $167,846,000 | $109,962,000 | $-91,206,000 | $-116,811,000 |
| EBIT | $161,295,000 | $103,248,000 | $-97,117,000 | $-120,196,000 |
| Diluted Average Shares | $29,951,000 | $29,740,000 | $27,752,000 | $25,492,000 |
| Basic Average Shares | $28,944,000 | $28,592,000 | $27,154,000 | $25,492,000 |
| Diluted NI Availto Com Stockholders | $204,831,000 | $89,159,000 | $10,932,000 | $-139,975,000 |
| Tax Provision | $-15,360,000 | $6,197,000 | $1,965,000 | $0 |
| Research And Development | $58,045,000 | $53,580,000 | $46,433,000 | $42,461,000 |
| Selling General And Administration | $146,741,000 | $113,626,000 | $98,289,000 | $77,735,000 |
| Other Special Charges | - | $37,500,000 | $-87,500,000 | $25,000,000 |
| Other Gand A | - | - | - | $77,735,000 |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,219,560,000 | $946,380,000 | $778,641,000 | $522,231,000 |
| Total Assets | $1,333,794,000 | $1,055,838,000 | $818,355,000 | $558,450,000 |
| Total Non Current Assets | $309,192,000 | $313,793,000 | $230,446,000 | $174,671,000 |
| Other Non Current Assets | $287,000 | $231,000 | $263,000 | $324,000 |
| Non Current Deferred Assets | $22,824,000 | $0 | - | - |
| Non Current Deferred Taxes Assets | $22,824,000 | $0 | - | - |
| Investmentin Financial Assets | $128,066,000 | $152,114,000 | $61,954,000 | $4,621,000 |
| Current Assets | $1,024,602,000 | $742,045,000 | $587,909,000 | $383,779,000 |
| Other Current Assets | $14,905,000 | $11,657,000 | $6,706,000 | $4,608,000 |
| Prepaid Assets | $14,006,000 | $1,617,000 | - | - |
| Inventory | $40,475,000 | $26,508,000 | $6,985,000 | $0 |
| Receivables | $127,425,000 | $104,746,000 | $42,040,000 | $0 |
| Accounts Receivable | $127,425,000 | $104,746,000 | $42,040,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $827,791,000 | $597,517,000 | $532,178,000 | $379,171,000 |
| Cash And Cash Equivalents | $496,304,000 | $344,865,000 | $358,328,000 | $161,900,000 |
| Debt | ||||
| Total Debt | $9,339,000 | $7,261,000 | $8,094,000 | $8,933,000 |
| Long Term Debt And Capital Lease Obligation | $7,568,000 | $6,044,000 | $6,620,000 | $7,372,000 |
| Current Debt And Capital Lease Obligation | $1,771,000 | $1,217,000 | $1,474,000 | $1,561,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $114,234,000 | $109,458,000 | $39,714,000 | $36,219,000 |
| Total Non Current Liabilities Net Minority Interest | $11,292,000 | $7,463,000 | $6,620,000 | $7,372,000 |
| Other Non Current Liabilities | $3,724,000 | $1,419,000 | - | - |
| Current Liabilities | $102,942,000 | $101,995,000 | $33,094,000 | $28,847,000 |
| Other Current Liabilities | $3,579,000 | $2,403,000 | $2,199,000 | $267,000 |
| Payables And Accrued Expenses | $97,592,000 | $98,375,000 | $29,421,000 | $27,019,000 |
| Payables | $14,157,000 | $9,273,000 | $6,092,000 | $4,024,000 |
| Total Tax Payable | $10,919,000 | $4,288,000 | $1,960,000 | $43,000 |
| Accounts Payable | $3,238,000 | $4,985,000 | $4,132,000 | $3,981,000 |
| Equity | ||||
| Common Stock Equity | $1,219,560,000 | $946,380,000 | $778,641,000 | $522,231,000 |
| Total Equity Gross Minority Interest | $1,219,560,000 | $946,380,000 | $778,641,000 | $522,231,000 |
| Stockholders Equity | $1,219,560,000 | $946,380,000 | $778,641,000 | $522,231,000 |
| Gains Losses Not Affecting Retained Earnings | $1,136,000 | $-190,000 | $638,000 | $-728,000 |
| Other Equity Adjustments | $1,136,000 | $-190,000 | $638,000 | $-728,000 |
| Retained Earnings | $24,163,000 | $-180,668,000 | $-269,827,000 | $-280,759,000 |
| Other | ||||
| Ordinary Shares Number | $29,192,000 | $28,794,000 | $28,236,673 | $25,763,743 |
| Share Issued | $29,192,000 | $28,794,000 | $28,236,673 | $25,763,743 |
| Tangible Book Value | $1,219,560,000 | $946,380,000 | $778,641,000 | $522,231,000 |
| Invested Capital | $1,219,560,000 | $946,380,000 | $778,641,000 | $522,231,000 |
| Working Capital | $921,660,000 | $640,050,000 | $554,815,000 | $354,932,000 |
| Capital Lease Obligations | $9,339,000 | $7,261,000 | $8,094,000 | $8,933,000 |
| Total Capitalization | $1,219,560,000 | $946,380,000 | $778,641,000 | $522,231,000 |
| Additional Paid In Capital | $1,194,261,000 | $1,127,238,000 | $1,047,830,000 | $803,718,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $7,568,000 | $6,044,000 | $6,620,000 | $7,372,000 |
| Current Capital Lease Obligation | $1,771,000 | $1,217,000 | $1,474,000 | $1,561,000 |
| Current Accrued Expenses | $83,435,000 | $89,102,000 | $23,329,000 | $22,995,000 |
| Investments And Advances | $128,066,000 | $152,114,000 | $61,954,000 | $4,621,000 |
| Available For Sale Securities | $128,066,000 | $152,114,000 | $61,954,000 | $4,621,000 |
| Net PPE | $158,015,000 | $161,448,000 | $168,229,000 | $169,726,000 |
| Accumulated Depreciation | $-31,281,000 | $-21,919,000 | $-12,827,000 | $-6,793,000 |
| Gross PPE | $189,296,000 | $183,367,000 | $181,056,000 | $176,519,000 |
| Leases | $27,227,000 | $25,673,000 | $25,068,000 | $24,217,000 |
| Construction In Progress | $8,108,000 | $5,778,000 | $7,291,000 | $131,331,000 |
| Other Properties | $40,008,000 | $36,624,000 | $34,271,000 | $19,914,000 |
| Machinery Furniture Equipment | $4,711,000 | $3,848,000 | $3,246,000 | $1,057,000 |
| Buildings And Improvements | $109,242,000 | $111,444,000 | $111,180,000 | $0 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $9,313,000 | $2,126,000 | $627,000 | $0 |
| Work In Process | $15,224,000 | $10,743,000 | $3,204,000 | $0 |
| Raw Materials | $15,938,000 | $13,639,000 | $3,154,000 | $0 |
| Other Short Term Investments | $331,487,000 | $252,652,000 | $173,850,000 | $217,271,000 |
| Other Investments | - | - | - | $4,621,000 |
| Preferred Stock | - | - | - | - |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $188,914,000 | $119,182,000 | $-100,603,000 | $-153,548,000 |
| Operating Activities | ||||
| Operating Cash Flow | $200,865,000 | $123,420,000 | $-88,804,000 | $-100,569,000 |
| Cash Flow From Continuing Operating Activities | $200,865,000 | $123,420,000 | $-88,804,000 | $-100,569,000 |
| Operating Gains Losses | $-5,953,000 | $-6,069,000 | $-105,092,000 | $-570,000 |
| Investing Activities | ||||
| Capital Expenditure | $-11,951,000 | $-4,238,000 | $-11,799,000 | $-52,979,000 |
| Investing Cash Flow | $-58,417,000 | $-163,439,000 | $82,638,000 | $-114,083,000 |
| Cash Flow From Continuing Investing Activities | $-58,417,000 | $-163,439,000 | $82,638,000 | $-114,083,000 |
| Net Other Investing Changes | $435,000 | - | $100,000,000 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $0 | $159,726,000 | $28,988,000 |
| Financing Cash Flow | $8,705,000 | $27,014,000 | $202,750,000 | $35,347,000 |
| Cash Flow From Continuing Financing Activities | $8,705,000 | $27,014,000 | $202,750,000 | $35,347,000 |
| Net Other Financing Charges | $-13,956,000 | $-5,386,000 | $-749,000 | $-649,000 |
| Net Common Stock Issuance | $0 | $0 | $159,726,000 | $28,988,000 |
| Common Stock Issuance | $0 | $0 | $159,726,000 | $28,988,000 |
| Other | ||||
| Income Tax Paid Supplemental Data | $15,673,000 | $5,665,000 | $0 | $0 |
| End Cash Position | $496,304,000 | $344,865,000 | $358,328,000 | $161,900,000 |
| Beginning Cash Position | $344,865,000 | $358,328,000 | $161,900,000 | $341,246,000 |
| Effect Of Exchange Rate Changes | $286,000 | $-458,000 | $-156,000 | $-41,000 |
| Changes In Cash | $151,153,000 | $-13,005,000 | $196,584,000 | $-179,305,000 |
| Proceeds From Stock Option Exercised | $22,661,000 | $32,400,000 | $43,773,000 | $7,008,000 |
| Net Investment Purchase And Sale | $-46,901,000 | $-159,201,000 | $-5,563,000 | $-61,104,000 |
| Sale Of Investment | $375,639,000 | $298,539,000 | $503,213,000 | $257,677,000 |
| Purchase Of Investment | $-422,540,000 | $-457,740,000 | $-508,776,000 | $-318,781,000 |
| Net PPE Purchase And Sale | $-11,951,000 | $-4,238,000 | $-11,799,000 | $-52,979,000 |
| Purchase Of PPE | $-11,951,000 | $-4,238,000 | $-11,799,000 | $-52,979,000 |
| Change In Working Capital | $-36,419,000 | $-14,457,000 | $-38,522,000 | $2,657,000 |
| Change In Other Current Liabilities | $1,702,000 | $586,000 | $-829,000 | $-647,000 |
| Change In Payables And Accrued Expense | $4,948,000 | $68,479,000 | $10,434,000 | $3,919,000 |
| Change In Accrued Expense | $4,122,000 | $67,468,000 | $10,535,000 | $5,173,000 |
| Change In Payable | $826,000 | $1,011,000 | $-101,000 | $-1,254,000 |
| Change In Account Payable | $826,000 | $1,011,000 | $-101,000 | $-1,254,000 |
| Change In Prepaid Assets | $-14,659,000 | $-8,909,000 | $-1,612,000 | $-615,000 |
| Change In Inventory | $-6,286,000 | $-11,907,000 | $-4,475,000 | $0 |
| Change In Receivables | $-22,124,000 | $-62,706,000 | $-42,040,000 | $0 |
| Changes In Account Receivables | $-22,124,000 | $-62,706,000 | $-42,040,000 | $0 |
| Other Non Cash Items | $684,000 | $652,000 | $217,000 | $34,000 |
| Stock Based Compensation | $54,514,000 | $49,127,000 | $39,933,000 | $33,230,000 |
| Amortization Of Securities | $-498,000 | $-1,706,000 | $-2,183,000 | $670,000 |
| Deferred Tax | $-22,845,000 | $0 | $0 | - |
| Deferred Income Tax | $-22,845,000 | $0 | $0 | - |
| Depreciation Amortization Depletion | $6,551,000 | $6,714,000 | $5,911,000 | $3,385,000 |
| Depreciation And Amortization | $6,551,000 | $6,714,000 | $5,911,000 | $3,385,000 |
| Depreciation | $6,551,000 | $6,714,000 | $5,911,000 | $3,385,000 |
| Gain Loss On Investment Securities | $-5,953,000 | $-6,069,000 | $-5,092,000 | $-570,000 |
| Net Income From Continuing Operations | $204,831,000 | $89,159,000 | $10,932,000 | $-139,975,000 |
| Change In Other Current Assets | - | - | $-64,000 | $-150,000 |
| Unrealized Gain Loss On Investment Securities | - | - | $-5,092,000 | $-570,000 |
| Gain Loss On Sale Of PPE | - | - | $27,000 | $72,000 |
Fetched: 2026-06-18